Protocol Ledger

NCT07724366 · Phase III · RECRUITING

A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis

Interventional Phase III clinical trial protocol NCT07724366 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-02 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07724366
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07724366
Protocol FieldVerified Registry Value
NCT IdentifierNCT07724366
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2026-09-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI